Microglia Activation and Neuroinflammatory Fatigue
Microglia—the brain’s resident immune cells—when chronically activated produce a neuroinflammatory state that suppresses neural circuit efficiency and generates fatigue and cognitive symptoms. This section presents the neuroinflammatory hypothesis of ME/CFS fatigue: evidence from neuroimaging (PET glial activation), CSF studies, and post-mortem data supporting microglial activation, and the downstream consequences for synaptic function, neurotransmitter reuptake, and the blood-brain barrier.
1 Neuroimaging Evidence: TSPO-PET and MRS
Positron emission tomography using the translocator protein (TSPO) ligand 11C-(R)-PK11195 provides the most direct in vivo evidence for microglial activation in ME/CFS. Nakatomi et al. (Nakatomi et al. 2014) demonstrated widespread neuroinflammation in 9 CFS/ME patients versus 10 controls, with significant TSPO binding increases in the cingulate cortex, hippocampus, amygdala, and thalamus, correlating with cognitive impairment severity (high certainty for PET methodology; small sample limits generalizability).
However, the evidence is not uncontested. Raijmakers et al. (Raijmakers et al. 2021) found no signs of neuroinflammation in 13 women with CFS using the same TSPO ligand, highlighting the importance of patient phenotyping, cohort selection, and methodological heterogeneity. VanElzakker et al. (VanElzakker, Brumfield, and Lara Mejia 2019) argue that most neuroimaging studies inadequately target the brainstem, which may be the primary site of neuroinflammatory activity.
Magnetic resonance spectroscopy (MRS) provides a complementary, non-invasive window: Mueller et al. (Mueller et al. 2020) found elevated lactate-to-creatine ratios in the right insula, thalamus, and cerebellum of ME/CFS patients, with brain temperature elevations consistent with inflammatory metabolic shifts. A meta-analysis of 65 neuroimaging studies confirmed hypoactivity in the insular and thalamic regions as the most consistent finding (Lee et al. 2024).
2 Microglial Phenotype Shift: From Surveillance to Reactivity
Under homeostatic conditions, microglia perform synaptic surveillance and phagocytic clearance. In ME/CFS, the neuroglial failure hypothesis proposes that persistent triggering factors (viral remnants, autoantibodies, metabolic danger signals) shift microglia toward a reactive M1-like state characterized by release of TNF-\(\alpha\), IL-1\(\beta\), IL-6, and reactive oxygen species (Renz-Polster et al. 2022). This reactivity may be self-perpetuating: microglial ROS production damages local neurons, releasing further danger signals that sustain activation.
Renz-Polster et al. (Renz-Polster et al. 2022) propose that impaired or pathologically reactive neuroglia—microglia, astrocytes, and oligodendrocytes—constitute the common denominator of ME/CFS pathobiology. Astrocytic glucose metabolism and microglial contributions to ME/CFS cognitive dysfunction are further documented in a comprehensive 2026 review (Xu et al. 2026). Under this model, microglial reactive state suppresses neural circuit efficiency and disrupts glial metabolic support to neurons, producing fatigue, cognitive impairment, and post-exertional malaise. The hypothesis extends naturally to Long COVID, which shows neuroglial activation on post-mortem analysis. Certainty: Medium (theoretical synthesis; not yet empirically tested as a whole; component mechanisms supported by animal and in vitro data).
3 Circulating Danger Signals and Microglial Activation
A key mechanistic question is how peripheral pathology in ME/CFS crosses into the brain to activate microglia. Gottschalk et al. (Gottschalk et al. 2022) demonstrated that serum from ME/CFS patients directly stimulates reactive oxygen species (ROS) and nitric oxide production in human microglial cells in vitro. The authors identified elevated ATG13 (autophagy-related protein 13) in ME/CFS serum as the active factor, acting via RAGE (receptor for advanced glycation end products) on microglial cell surfaces. Neutralization of ATG13 substantially reduced the oxidative stress response, implicating impaired autophagy as an upstream driver of neuroinflammation (certainty: Low-Medium; in vitro only; requires in vivo validation).
4 Purinergic Signaling and Microglial Danger Response
Microglia express P2X and P2Y purinergic receptors that respond to extracellular ATP released from damaged or metabolically stressed cells. In the cell danger response (CDR) framework, persistent purinergic signaling maintains microglia in a reactive state. The adenosine A2A receptor, upregulated on reactive microglia, further modulates this activation cycle. In ME/CFS, where post-exertional metabolic disturbance is cardinal, exercise-induced ATP release may serve as a recurring microglial activation trigger, providing a mechanistic link between physical exertion and neuroinflammatory symptom exacerbation.
5 Complement Cascade and Synaptic Pruning
Reactive microglia co-opt the complement cascade to tag synapses for elimination. Under normal developmental conditions, C1q, C3, and C4 opsonize weak synapses for phagocytosis via microglial CR3 receptors—a process essential for circuit refinement. In ME/CFS, chronic microglial reactivity may sustain inappropriate synaptic pruning in adulthood, with potential consequences for cognitive processing speed and synaptic transmission efficiency (Renz-Polster et al. 2022).
By analogy with neurodegenerative conditions in which complement-mediated synaptic loss precedes neuronal death, ME/CFS neuroinflammation may drive a subthreshold but functionally significant loss of synaptic contacts in prefrontal and hippocampal circuits. This mechanism could explain “brain fog” disproportionate to neuronal loss. The hypothesis is speculative in ME/CFS specifically and requires direct complement and synapse density measurements in ME/CFS post-mortem tissue. Certainty: Low (extrapolated from Alzheimer’s disease and developmental biology literature; no ME/CFS-specific data yet).
6 Therapeutic Modulation of Microglial Activation
Two agents with established anti-neuroinflammatory profiles have been investigated in ME/CFS: low-dose naltrexone (LDN) and minocycline.
Low-dose naltrexone. At doses of 1.5–4.5mg, naltrexone antagonizes toll-like receptor 4 (TLR4) on microglial cells, interrupting a key activation signal and reducing downstream cytokine release (Younger, Parkitny, and McLain 2014) (Bolton, Chapman, and Van Marwijk 2020) (Polo et al. 2019). The mechanism is distinct from its opioid antagonism at higher doses. Retrospective and open-label data suggest symptom benefit in subsets of ME/CFS patients, though randomized controlled trial evidence is lacking.
Minocycline. Minocycline, a tetracycline antibiotic with independent anti-inflammatory and neuroprotective properties, inhibits microglial activation and reduces ROS production. Miwa (Miwa 2021) conducted an open-label trial in 100 ME patients (42-day course, 100mg/day), reporting a favorable performance-status response in 27% of participants, with best outcomes in those within six months of disease onset. A subsequent pilot study confirmed higher response rates (80%) in early-stage patients. As Numata (Numata 2021) observes, the modest and heterogeneous response underscores that neuroinflammation represents only one pathobiological thread in ME/CFS, and patient stratification by disease stage and phenotype is essential before trialling targeted anti-neuroinflammatory agents.
Therapeutic benefit from anti-microglial agents (LDN, minocycline) may be concentrated in early-stage ME/CFS, when active neuroinflammation is more likely to be driving symptoms rather than fixed structural or epigenetic changes. In later stages, microglial modulation alone may be insufficient without addressing upstream triggers (persistent viral antigens, autoantibodies) and downstream consequences (glymphatic failure, synaptic remodeling). Certainty: Low-Medium (mechanistic plausibility supported; clinical evidence limited to open-label data).